Advertisement

Perioperative Arrhythmien

Vermeidung, Erkennung, Bewertung, Therapie
  • Martin N. Vicenzi
Chapter
  • 23 Downloads

Zusammenfassung

Die Vermeidung, Erkennung, Bewertung und Therapie perioperativer Herzrhythmusstörungen gehören im Sinne der Erhaltung stabiler Kreislaufverhältnisse und der Patientensicherheit zu den zentralen Aufgaben des Anästhesisten und Intensivmediziners. Der Detektionsgrad intraoperativer Rhythmusstörungen hängt von Qualität und Dauer des EKG-Monitorings ab. So wird dieser in einer Multizenterstudie an mehr als 17.000 Patienten unter Allgemeinanästhesie mit über 70% angegeben [16]. Schwerwiegende, rhythmusassoziierte Komplikationen ergaben sich jedoch nur in 1,6%. In selektierten Hochrisikogruppen oder bei großen Herz- oder Thoraxeingriffen liegt diese Detektionsrate jenseits der 90% und die daraus resultierende Komplikationsrate deutlich über den oben genannten 1,6% [16]. Daraus wird vordergründig abgeleitet, dass Herzrhythmusstörungen zwar relativ häufige Ereignisse sind, diese aber am Kollektiv gemessen nur selten zu ernsthafteren Problemen führen.

Keywords

Anesthesia Cardiac arrhythmias Amiodarone Perioperative risk 

Abkürzungen

CKB

Ca-Kanalblocker (Verapamil, Diltiazem)

CAST

cardiac arrhythmia suppression trial

AICD

automatic implantable cardioverter defibrillator

WPW

Wolff Parkinson White

CABG

coronary artery bypass grafting

PTCA

percutaneous transluminal coronary angioplasty

HTX

Herztransplantation

KI

Kontraindikation

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Akhtar M, Breithardt G, Camm AJ, Coumel P., et al., (1990) CAST and beyond. Implications of the cardiac arrhythmia suppression trial. Task force of the working group on arrhythmias of the European Society of Cardiology. Circulation 81: 1123–1127PubMedCrossRefGoogle Scholar
  2. 2.
    Akiyama T, Pawitan Y, Greenberg H, Kuo CS, et al., (1991) Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the cardiac arrhythmia suppression trial. CAST investigators. Am J Cardiol 68: 1551–1555PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson JL, Prystowsky EN (1999) Sotalol: an important new antiarrhythmic. Am Heart J 137: 388–409PubMedCrossRefGoogle Scholar
  4. 4.
    Atlee JL (1997) Perioperative cardiac dysrhythmias: diagnosis and management. Anesthesiology 86: 1397–1424PubMedCrossRefGoogle Scholar
  5. 5.
    Balser JR (1997) The rational use of intravenous amiodarone in the perioperative period. Anesthesiology 86: 974–987PubMedCrossRefGoogle Scholar
  6. 6.
    Cheema AN, Sheu K, Parker M, Kadish AH, et al., (1998) Nonsustained ventricular tachycardia in the setting of acute myocardial infarction. Tachycardia characteristics and their prognostic implications. Circulation 98: 2030–2036PubMedGoogle Scholar
  7. 7.
    Cohn JN, Johnson GR, Shabetai R, Loeb H., et al., (1993) Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 87: 5–16Google Scholar
  8. 8.
    Connolly SJ (1999) Prophylactic antiarrhythmic therapy for the prevention of sudden death in high-risk patients: drugs and devices. Eur Heart J 1: C31–C35CrossRefGoogle Scholar
  9. 9.
    Connolly SJ (1999) Evidence-based analysis of amiodarone efficacy and safety. Circulation 100: 2025–2034PubMedGoogle Scholar
  10. 10.
    Connolly SJ (1999) Meta-analysis of antiarrhythmic drug trials. Am J Cardiol 4: 90R–93RCrossRefGoogle Scholar
  11. 11.
    Discher TJ, Kumar P, Miller SM, Mayer RC (1994) Antiarrhythmic drugs should be used to suppress ventricular ectopy in the perioperative period. J Cardiothorac Vasc Anesth 8: 699–703PubMedCrossRefGoogle Scholar
  12. 12.
    Duffee DF, Shen WK, Smith HC (1998) Suppression of frequent premature ventricular contractions and improvement of left ventricular function in patients with presumed idiopathic dilated cardiomyopathy. Mayo Clin Proc 73: 430–433PubMedCrossRefGoogle Scholar
  13. 13.
    Eckardt L, Haverkamp W, Johna R, Bocker D., et al.,(2000) Arrhythmias in heart failure: current concepts of mechanisms and therapy. J Cardiovasc Electrophysiol 11: 106–117PubMedCrossRefGoogle Scholar
  14. 14.
    Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, et al., (1993) Mortality following ventricular arrhythmia suppression by encainide,flecainide, and moricizine after myocardial infarction. The original design concept of the cardiac arrhythmia suppression trial (CAST). JAMA 270: 2451–2455PubMedCrossRefGoogle Scholar
  15. 15.
    Farre J, Romero J, Rubio JM, Ayala R., et al., (1999) Amiodarone and “primary” prevention of sudden death: critical review of a decade of clinical trials. Am J Cardiol 11: 55D–63DCrossRefGoogle Scholar
  16. 16.
    Forrest JB, Cahalan MK, Rehder K, Goldsmith CH, et al., (1990) Multicenter study of general anesthesia. II. Results. Anesthesiology 72: 262–268PubMedCrossRefGoogle Scholar
  17. 17.
    Ghali JK, Kadakia S, Cooper RS, Liao YL (1991) Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. JACC 17: 1277–1282PubMedGoogle Scholar
  18. 18.
    Gomez MN (1998) Magnesium and cardiovascular disease. Anesthesiology 89: 222–240PubMedCrossRefGoogle Scholar
  19. 19.
    Greene HL, Roden DM, Katz RJ, Woosley RL, et al., (1992) The cardiac arrhythmia suppression trial: first castthen cast-II. JACC 19: 894–898PubMedGoogle Scholar
  20. 20.
    Julian DG, Camm AJ, Frangin G, Janse MJ, et al., (1997) Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European myocardial infarct amiodarone trial investigators. Lancet 349: 667–674PubMedCrossRefGoogle Scholar
  21. 21.
    Katritsis D, Camm AJ (1994) Antiarrhythmic drug classifications and the clinician: a gambit in the land of chaos. Clin Cardiol 17: 142–148PubMedCrossRefGoogle Scholar
  22. 22.
    Kennedy HL (1997) Beta-blocker prevention of proarrhythmia and proischemia: clues from CAST, CAMIAT, and EMIAT. Am J Cardiol 80: 1208–1211PubMedCrossRefGoogle Scholar
  23. 23.
    Klein H, Auricchio A, Reek S, Geller C. (1999) New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT II. Am JCardiol 11: 91D–97DCrossRefGoogle Scholar
  24. 24.
    Kulier AH, Novalija E, Hogan Q, Vicenzi MN, et al., (1999) The effects of the new antiarrhythmic E 047/1 on postoperative ischemia-induced arrhythmias in dogs. Anesth Analg 89: 1393–1399PubMedGoogle Scholar
  25. 25.
    Levy S, Ricard P. (1997) Using the right drug: a treatment algorithm for regular supraventricular tachycardias. Eur Heart J18: C27–C32Google Scholar
  26. 26.
    Mahla E, Rotman B, Rehak P, Atlee JL, et al., (1998) Perioperative ventricular dysrhythmias in patients with structural heart disease undergoing noncardiac surgery. Anesth Analg 86: 16–21PubMedGoogle Scholar
  27. 27.
    Mangano DT, Layug EL, Wallace A, Tateo I. (1996) Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter study of perioperative ischemia research group. N Engl J Med 335: 1713–1720PubMedCrossRefGoogle Scholar
  28. 28.
    Mehta Y, Swaminathan M, Juneja R, Saxena A., et al., (1998) Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian gambit. J Cardiothorac Vase Anesth 12: 221–224CrossRefGoogle Scholar
  29. 29.
    Naccarelli GV, Wolbrette DL, Dell’Orfano JT, Patel HM, et al.,(2000) Amiodarone: What have we learned from clinical trials? Clin Cardiol 23: 73–82PubMedCrossRefGoogle Scholar
  30. 30.
    Naccarelli GV, Wolbrette DL, Patel HM, Luck JC (2000) Amiodarone: clinical trials. Curr Opin Cardiol 15: 64–72PubMedCrossRefGoogle Scholar
  31. 31.
    Packer DL, Munger TM, Johnson SB, Cragun KT (1997) Mechanism of lethal proarrhythmia observed in the cardiac arrhythmia suppression trial: role of adrenergic modulation of drug binding. Pacing Clin Electrophysiol 20: 455–467PubMedCrossRefGoogle Scholar
  32. 32.
    Roghi A, Palmieri B, Crivellaro W, Sara R., et al., (1999) Preoperative assessment of cardiac risk in noncardiac major vascular surgery. Am J Cardiol 15: 169–174CrossRefGoogle Scholar
  33. 33.
    The’ sicilian Gambit’. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The task force of the working group on arrhythmias of the European Society of Cardiology. (1991) Eur Heart J12: 1112-1131Google Scholar
  34. 34.
    Skanes AC, Green MS (1996) What have clinical trials taught us about proarrhythmiaä Can J Cardiol 20B–26BGoogle Scholar
  35. 35.
    Starmer CF (1997) The cardiac vulnerable period and reentrant arrhythmias: targets of antiand proarrhythmie processes. Pacing Clin Electrophysiol 20: 445–454PubMedCrossRefGoogle Scholar
  36. 36.
    Steinbach KK, Merl O, Frohner K, Hief C., et al., (1994) Hemodynamics during ventricular tachyarrhythmias. Am Heart J127: 1102–1106CrossRefGoogle Scholar
  37. 37.
    Touboul P. (1999) A decade of clinical trials: CAST to AVID. Eur Heart J 1: C2–C10Google Scholar
  38. 38.
    Verduyn SC, Vos MA, Leunissen HD, Opstal JM van., et al., (1999) Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias. J Cardiovasc Pharmacol 33: 212–222PubMedCrossRefGoogle Scholar
  39. 39.
    Vicenzi MN, Mahla E, Neuray M, Gombotz H. (2000) Severe ventricular dysrhythmias after cardiac surgery treated with the fast acting amiodarone derivative E 047/1 (Abstract). Eur J Anaesthesiol 19: (A 522) 159CrossRefGoogle Scholar
  40. 40.
    Wahr JA, Parks R, Boisvert D, Comunale M., et al.,(1999) Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients. Multicenter study of perioperative ischemia research group. JAMA 281: 2203–2210PubMedCrossRefGoogle Scholar
  41. 41.
    Wallace A, Mangano DT (1997) Use of betablockade to prevent death after noncardiac surgery. West J Med 166: 203–204PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • Martin N. Vicenzi
    • 1
  1. 1.Universitätsklinik für Anästhesie und IntensivmedizinLandeskrankenhaus und Universitätsklinikum GrazGrazÖsterreich

Personalised recommendations